Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer
Clinical trial NCT02049957 · COMPLETED
Trial details
- NCT number
- NCT02049957
- Sponsor
- Calithera Biosciences, Inc
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-02-13
- Primary completion
- 2018-06-29
- Enrollment
- 118
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.